So far, the FDA and EMA have approved six ADC drugs for patients with solid tumors. Fig. 1 depicts the composition of each ADC (targeting antigen, mAb type, payload, and linker), […]
The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role […]
The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role […]
- 2 of 2
- « Previous
- 1
- 2